Guardant Health Inc (NASDAQ:GH) Director Stanley J. Meresman sold 10,000 shares of Guardant Health stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $76.36, for a total transaction of $763,600.00.
Shares of GH traded up $1.11 during mid-day trading on Tuesday, reaching $76.09. The company’s stock had a trading volume of 14,435 shares, compared to its average volume of 1,083,396. The stock has a market cap of $7.20 billion and a PE ratio of -26.86. Guardant Health Inc has a 52 week low of $27.04 and a 52 week high of $112.21. The company’s fifty day moving average price is $92.05 and its two-hundred day moving average price is $82.42.
Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.21. The firm had revenue of $53.98 million during the quarter, compared to analyst estimates of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The business’s quarterly revenue was up 178.5% on a year-over-year basis. During the same period in the previous year, the business posted ($1.75) EPS. As a group, sell-side analysts expect that Guardant Health Inc will post -1.27 EPS for the current fiscal year.
GH has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Canaccord Genuity reiterated a “buy” rating and set a $125.00 target price (up from $96.00) on shares of Guardant Health in a research report on Wednesday, August 7th. Zacks Investment Research lowered shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, Cowen set a $110.00 target price on shares of Guardant Health and gave the company a “buy” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $111.80.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.